Monopar Therapeutics Inc. Closes $19.2 Million Public Offering of Common Stock

Monopar Therapeutics Inc. announced the closing of a best efforts public offering of shares of its common stock at a public offering price of $16.25 per share, resulting in aggregate gross proceeds of approximately $19.2 million. The net proceeds from the offering will be used for general corporate purposes, including research and development expenditures, clinical trial expenditures, manufacture and supply of product, and working capital.